W
Wenbin Liang
Researcher at University of Ottawa
Publications - 52
Citations - 1813
Wenbin Liang is an academic researcher from University of Ottawa. The author has contributed to research in topics: Wnt signaling pathway & Medicine. The author has an hindex of 19, co-authored 47 publications receiving 1316 citations. Previous affiliations of Wenbin Liang include Cedars-Sinai Medical Center & Jilin University.
Papers
More filters
Journal ArticleDOI
Hexokinase Is an Innate Immune Receptor for the Detection of Bacterial Peptidoglycan
Andrea J. Wolf,Christopher N. Reyes,Wenbin Liang,Courtney A. Becker,Kenichi Shimada,Matthew L. Wheeler,Hee Cheol Cho,Narcis I. Popescu,K. Mark Coggeshall,Moshe Arditi,David M. Underhill +10 more
TL;DR: This study shows that a metabolic enzyme can act as a pattern recognition receptor and is caused by release of N-acetylglucosamine that is detected in the cytosol by the glycolytic enzyme hexokinase.
Journal ArticleDOI
Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18
TL;DR: Conversion of rodent cardiomyocytes to SAN cells in vitro and in vivo by expression of Tbx18, a gene critical for early SAN specification is demonstrated, opening new prospects for bioengineered pacemakers.
Journal ArticleDOI
SHOX2 Overexpression Favors Differentiation of Embryonic Stem Cells into Cardiac Pacemaker Cells, Improving Biological Pacing Ability
Vittoria Ionta,Vittoria Ionta,Wenbin Liang,Elizabeth H. Kim,Reza Rafie,Alessandro Giacomello,Eduardo Marbán,Hee Cheol Cho,Hee Cheol Cho +8 more
TL;DR: Overexpression of SHOX2 during ESC differentiation upregulated the pacemaker gene program, resulting in enhanced automaticity in vitro and induced biological pacing upon transplantation in vivo, providing a strategy for enriching the cardiac pacemaker cell population from ESCs.
Journal ArticleDOI
NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes.
TL;DR: This review summarizes recent progress regarding the NLRP3 inflammasome as a potential treatment for ischemic stroke in patients with diabetes and the maturation of proinflammatory cytokines such as interleukin (IL)-1β and IL-18.
Journal ArticleDOI
Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction.
Sarah McLaughlin,Brian McNeill,James Podrebarac,Katsuhiro Hosoyama,Veronika Sedláková,Gregory Cron,David Smyth,Richard Seymour,Keshav Goel,Wenbin Liang,Katey J. Rayner,Marc Ruel,Erik J. Suuronen,Emilio I. Alarcon +13 more
TL;DR: Functional recovery post-MI is shown using rHCI by promoting a healing environment, cardiomyocyte survival, and less pathological remodeling of the myocardium using injectable recombinant human collagen type I and III matrices that are able to limit adverse remodelling and improve function of theMyocardium.